Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANGAU: Glutaminergic Transmission in Autism
NCT02719951Phase 1Completed
- Sponsor
- University Hospital Tours
- Start
- Apr 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]FPEB (3 arms), sponsored by University Hospital Tours. Primary endpoint: Cerebral glutaminergic activity assessed by binding potential of [18F]FPEB at 3 years. Started Apr 2016; status: completed.
02
Drugs
[18F]FPEB
Beyond the preview
Go deeper on NCT02719951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719951.